Search Results
Your search for ,ShE matches 5598 pages
Showing 1151 - 1200Expert Point of View: Callisia N. Clarke, MD, MS, FACS, FSSO
Moderator of the press conference at the 2023 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care, Callisia N. Clarke, MD, MS, FACS, FSSO, Assistant Professor of Surgery, Medical College of Wisconsin, shared insights on the transition of circulating tumor DNA...
Using Circulating Tumor DNA to Predict Early Recurrence of Soft-Tissue Sarcomas
Circulating tumor DNA (ctDNA) may transform disease monitoring and guide treatment for soft-tissue sarcomas, according to data presented at the 2023 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care.1 Findings of a retrospective review showed that 85% of patients...
Expert Point of View: Yelena Y. Janjigian, MD
The GLOW study’s invited discussant, Yelena Y. Janjigian, MD, Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, New York, said the GLOW findings are “practice-changing,” validating that high claudin-18.2 (CLDN18.2) expression as an important biomarker in...
Expert Point of View: Rebecca Arend, MD, MSH and Ilaria Colombo, MD
“Endometrial cancer is the most frequently diagnosed gynecologic malignancy in the United States, and it is the only one where the mortality has actually risen over the past 40 years,” noted Rebecca Arend, MD, MSH, Associate Professor at the University of Alabama and Associate Scientist in the...
COVID-19 Pandemic May Have Disrupted Cancer Reporting in 2020 and Beyond
Investigators have uncovered factors contributing to the COVID-19 pandemic’s destabilization of the usual patterns of cancer care, described specific ways that National Cancer Database data models were impacted by the pandemic, and offered guidance to cancer centers across the United States on how...
Investigational Deep Learning Model May Help Stratify Risk of Distant Recurrence in Patients With Endometrial Cancer
An investigational deep learning model requiring one histopathologic slide may be effective at predicting the risk of distant recurrence in patients with endometrial cancer, according to novel findings presented by Fremond et al at the American Association for Cancer Research (AACR) Annual Meeting...
Olaparib Plus Ceralasertib May Benefit Pediatric Patients With Cancer Who Have DNA Replication and/or Damage Repair–Deficient Tumors
Researchers have found that a combination of the PARP inhibitor olaparib and the investigational ATR inhibitor ceralasertib showed clinical benefit in pediatric patients with solid tumors exhibiting DNA replication and/or damage repair deficiencies, according to new findings presented by Gatz et al ...
Study Finds Lung Cancer Incidence Rates Vary Significantly Among Florida’s Black and Hispanic Ethnic Subgroups
An analysis of lung cancer incidence rates showed wide variations among the racial and ethnic subgroups in Florida’s Black and Hispanic population, according to data presented by Cranford et al at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract 1902/8). Study...
Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma
Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by Kendra et al at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract...
First-Line Pembrolizumab Plus Gemcitabine/Cisplatin May Improve Overall Survival in Advanced Biliary Tract Cancer
The addition of pembrolizumab to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the phase III KEYNOTE-966 clinical trial, which were presented by Robin Katie Kelley, MD, and colleagues at the...
Pragmatica-Lung Trial Begins Enrolling Patients With NSCLC Who Did Not Respond to Previous Therapy
The National Cancer Institute (NCI) announced that it has helped launch the randomized phase III Pragmatica-Lung trial examining the efficacy of ramucirumab plus pembrolizumab in treating patients with advanced non–small cell lung cancer (NSCLC). The new study is one of the first NCI-supported...
New Study Examines Cancer-Related Mortality Rates During First Year of COVID-19 Pandemic
U.S. mortality rates with cancer as the underlying or primary cause decreased during the first year of the COVID-19 pandemic, whereas mortality rates with cancer as a contributing cause increased, according to a new study published by Zhao et al in JCO Oncology Practice. The findings demonstrated...
Financial Toxicity of Cancer May Impact Partner’s Quality of Life
Researchers have discovered that the financial impact of an individual’s cancer diagnosis may also impact a partner’s health-related quality of life, according to a new study published by Ghazal et al in JAMA Network Open. “When you think of key developmental milestones young adults expect to...
Arlene O. Siefker-Radtke, MD, on Urothelial Cancer: Emerging Therapies
Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, provides an overview of the emerging treatments for urothelial cancer, including several new agents in the antibody-drug conjugate and tyrosine kinase inhibitor classes. She describes the clinical activity and...
Prior CTLA-4 Inhibition May Influence Response to PD-1 Inhibitors in Patients With Advanced Melanoma
Researchers have found that responses to PD-1 inhibitor treatment in patients with advanced melanoma may depend on whether they had received previous treatment with CTLA-4 inhibitors, according to a new study published by Campbell et al in Cancer Cell. “In our large set of data, features that have...
Healthy Lifestyles May Be Associated With Reduced Mortality Risk in Pediatric Cancer Survivors
Researchers have provided strong evidence that a healthy lifestyle may significantly reduce mortality in adults who have survived pediatric cancer, according to a new study published by Dixon et al in The Lancet. The findings are among the first to reveal that the specific primary causes of...
Surgeon and Cancer Researcher Kelly M. McMasters, MD, PhD, Celebrates the ‘Miracle of Translational Science’
In this installment of our Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kelly M. McMasters, MD, PhD, who, for the past 27 years, has directed a basic and translational science lab studying adenovirus-mediated cancer gene therapy and melanoma biomarkers....
Elizabeth M. Jaffee, MD, FAACR, to Receive 2023 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
The American Association for Cancer Research (AACR) will honor Elizabeth M. Jaffee, MD, FAACR, AACR Past President, with the 2023 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the 2023 AACR Annual Meeting, to be held on April 14–19 in Orlando,...
Genetics Likely Caused My Small Cell Lung Cancer
When I was diagnosed with lung cancer, in 2007, I asked the physician not to tell me the type, stage, or prognosis. I was about to start nursing school and was aware enough about the disease to know that not many people survived. I’ve since discovered that I had stage 3B small cell lung cancer,...
Kerin Adelson, MD, Named MD Anderson Chief Quality and Value Officer
The University of Texas MD Anderson Cancer Center has announced the appointment of Kerin Adelson, MD, as the institution’s Chief Quality and Value Officer. An accomplished clinician and researcher with extensive leadership experience in cancer care, Dr. Adelson will also hold a faculty appointment...
Which Patients With Breast Cancer Can Omit Radiotherapy?
Although advances in radiation therapy have rendered this treatment modality more tolerable, they have not completely eliminated the burden of radiation-related toxicity. In an ideal setting, clinicians would be able to identify patients whose risk of recurrence is sufficiently low that they can...
Early-Stage Triple-Negative Breast Cancer: Optimizing Therapy
The management of early-stage triple-negative breast cancer has been evolving at a fast pace, thanks largely to the discovery that immune checkpoint blockade can be effective in this subtype. At the 2023 Miami Breast Cancer Conference, Priyanka Sharma, MD, Professor of Medicine, University of...
Expert Point of View: Callisia N. Clarke, MD, MS, FACS, FSSO
Moderator of the press conference at the 2023 International Conference on Surgical Cancer Care, Callisia N. Clarke, MD, MS, FACS, FSSO, Assistant Professor of Surgery at the Medical College of Wisconsin, highlighted the significance of the 80% response rates to neoadjuvant immunotherapy in primary...
Two Cancer Experts to Head New Tisch Cancer Hospital at Mount Sinai Hospital
Two cancer experts have been named to lead Mount Sinai’s new Tisch Cancer Hospital, which is under development and expected to open in 2027. Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer and Vice President of Cancer Clinical Affairs, and Ash Tewari, MBBS, MCh, has been...
Training Oncology Nurses on Primary Palliative Care May Improve End-of-Life Care and Spur Creation of Advance Directives for Patients With Cancer
Specially trained oncology infusion room nurses may be capable of improving advance care planning for patients with advanced cancer at the end of life, according to a new study published by Cohen et al in JNCCN—Journal of the National Comprehensive Cancer Network. Background “Advance care planning...
Elena Ratner, MD, MBA on Sexual Identity and Function in Cancer Survivors
Elena Ratner, MD, MBA, of Yale Cancer Center/Smilow Cancer Hospital, discusses sexuality, intimacy, fertility, and menopause as important aspects of women’s cancer survivorship and the many effects of treatment on these issues. They often go unacknowledged in the medical community, Dr. Ratner says, ...
Ella A. Kazerooni, MD, on Lung Cancer Screening: Benefits and Challenges
Ella A. Kazerooni, MD, of the University of Michigan Rogel Cancer Center, discusses reducing cancer deaths in the United States by identifying patients at risk for lung cancer. Engaging with primary care physicians and facilitating referrals are keys to a successful lung cancer screening program,...
Initiative for Managing Adverse Events of Immunotherapy Leads to Clinical Practice Changes at MD Anderson
The inaugural MD Anderson Clinical Education Symposium on Immunotherapy Toxicity Management (IOTOX) welcomed more than 250 international attendees, both virtually and in person at The University of Texas MD Anderson Cancer Center in Houston on December 3, 2022. The symposium focused on bringing the ...
Nivolumab Injected Directly Into Spinal Fluid May Be Safe and Effective for Some Patients With Melanoma Who Have Leptomeningeal Disease
Researchers have found that a novel approach to administer intrathecal and intravenous nivolumab has proven safe and improved survival in a subset of patients who developed leptomeningeal disease from metastatic melanoma, according to a new study published by Glitza Olivia et al in Nature ...
Researchers Uncover How Advanced Melanoma May Resist Treatment at the End of Life
Researchers have revealed the potential mechanisms contributing to treatment resistance in patients with melanoma at the end of life, according to a new study published by Spain et al in Cancer Discovery. “These results present the most detailed picture yet of what melanoma looks like at the final...
Clinical Trial Participation May Be Associated With Improved Overall Survival in Patients With Ovarian Cancer
Investigators have found that patients with platinum-resistant epithelial ovarian cancer who participate in clinical trials may have higher rates of overall survival compared with those who don’t participate in clinical trials, according to findings presented by Morton et al at the Society of...
Time-Related and Financial Burdens May Impact Quality of Life for Patients With Gynecologic Cancer
Time-related and financial burdens may be detrimental to the quality of life of patients with gynecologic cancer as well as cancer survivors, according to the findings from two new studies presented by Ackroyd et al and Adjei et al at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on ...
Researchers Find No Significant Differences in Overall Survival Among Patients With Platinum-Sensitive Recurrent Ovarian Cancer Who Received Niraparib Maintenance Therapy vs Placebo
Researchers have found no significant differences in overall survival between patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib or placebo, according to new findings presented by Matulonis et...
Positive Outcomes Demonstrated in Patients With Ovarian Cancer Treated With Olaparib Prior to Surgical Intervention and Subsequent Chemotherapy
Treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib prior to surgical intervention and chemotherapy has demonstrated the potential for favorable surgical options, manageable adverse events, and positive health outcomes in patients with ovarian cancer who have a germline...
Risk of Cervical Cancer May Be Twice as High in Patients With Mental Illnesses
Patients who have a mental illness, neuropsychiatric disability, or substance use disorder may be less likely to undergo gynecological smear tests and may have over twice the risk of developing cervical cancer, according to a new study published by Hu et al in The Lancet Public Health. The findings ...
Obesity May Contribute to Breast Cancer Risk in High-Risk Patients With BRCA Mutations
Obesity may spur DNA damage in the breast tissue of patients who carry BRCA1 or BRCA2 mutations, possibly contributing to breast cancer development in patients who are already at a higher risk of the disease, according to a new study published by Bhardwaj et al in Science Translational Medicine....
ASCO Updates Guideline on Sacituzumab Govitecan-hziy in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
ASCO has released a rapid recommendation update to the guideline on chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer, addressing the use of sacituzumab govitecan-hziy in patients with endocrine-resistant, hormone receptor–positive,...
FORMULA-509: Intensified Postoperative Regimen May Be of Benefit in Subset of High-Risk Prostate Cancer
The addition of abiraterone acetate and apalutamide to standard of care gonadotropin-releasing hormone (GnRH) agonist for 6 months and radiation therapy failed to improve progression-free survival and metastasis-free survival after prostatectomy compared to bicalutamide plus a GnRH agonist and...
Expert Point of View: Elena Castro, MD, PhD
The formal discussant of the TALAPRO-2 trial, Elena Castro, MD, PhD, took issue with the conclusion of Dr. Neeraj Agarwal and colleagues that these results support the use of talazoparib plus enzalutamide as a first-line treatment of patients with metastatic castration-resistant prostate cancer,...
The Will to Go On
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Walks on a Beach With an Inspiring Grandfather Led to a Career in Cancer Research and Drug Development for Vivek Subbiah, MD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Vivek Subbiah, MD, Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine Division, at The University of Texas MD Anderson Cancer Center, ...
Expert Point of View: Monica Chatwal, MD
Medical oncologist Monica Chatwal, MD, of Moffitt Cancer Center, Tampa, Florida, commented on the take-home points from the ARASENS trial. “The ARASENS trial continues to show a survival benefit for a triplet therapy approach in metastatic hormone-sensitive prostate cancer with androgen-deprivation ...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
Patricia M. LoRusso, DO, PhD (hc), Elected 2023–2024 AACR President-Elect
The members of the American Association for Cancer Research (AACR) have elected Patricia M. LoRusso, DO, PhD (hc), as the President-Elect for the 2023 to 2024 term. Dr. LoRusso will become President-Elect on Monday, April 17, during the Annual Business Meeting of Members at the AACR Annual Meeting...
Nuances in Breast Cancer Imaging for Screening and Surveillance
Breast cancer screening and imaging-based surveillance after treatment remain suboptimal, largely because of confusion in the guidelines and the fact that dense breasts are too often ignored, according to Elizabeth Morris, MD, FACR, FSBI, FISMRM, Professor and Chair of the Department of Radiology...
Understanding Fertility Issues in Young Patients With Breast Cancer
Young women with breast cancer have many concerns about their future fertility. How confident are you in discussing their chances of a future pregnancy, the effect of breast cancer treatment and fertility interventions on these offspring, and their risk of a compromised oncologic outcome after...
Does Discrimination Accelerate Aging in Black Cancer Survivors?
Investigators have found that Black cancer survivors who reported high levels of discrimination showed greater biological aging and frailty than those who reported lower levels of discrimination, according to a new study published by Mandelblatt et al in the journal Cancer. Background...
COVID-19 Vaccination Rates May Be Lower in Patients With Cancer Who Have Comorbidities, Certain Types of Cancer, and Specific Sociodemographic Factors
Investigators have found that patients undergoing treatment for cancer who have comorbidities, metastatic solid or non–B-cell hematologic malignancies, and those living in areas with lower levels of education and higher levels of unemployment may have lower rates of COVID-19 vaccination, according...
New Research Highlights the Negative Impact of Continued Exclusion of Patients With African Ancestry From Research on Cancer Genomics
Researchers have revealed how the lack of genomic research for individuals with African ancestry—particularly those from the Sub-Saharan region—may be hampering efforts to reduce disparities for patients with prostate cancer, according to a new study published by Gheybi et al in JNCCN–Journal of...
Elizabeth Smyth, MD, Offers Insight on KEYNOTE-859 Findings
The invited discussant of KEYNOTE-859,1 Elizabeth Smyth, MD, consultant in gastrointestinal oncology at Cambridge University Hospitals NHS Foundation Trust in the United Kingdom, called the findings “practice-changing” but cautioned that better patient selection is needed to optimally apply them....
